 |
|
Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
16. Eliminating a Common Bacterium Reduces Risk of Second Gastric Cancer
(Posted: 09/02/2008) - When the bacterium Helicobacter pylori is eliminated in patients who are treated for early stage gastric cancer, the risk of developing a second gastric cancer decreases by two-thirds, according to the Aug. 2, 2008, issue of The Lancet.
17. Follicular Lymphoma Treatment Better With Rituximab
(Posted: 05/15/2005, Updated: 08/18/2008) - In patients with newly diagnosed follicular lymphoma, the addition of rituximab (Rituxan®) to the standard chemotherapy regimen CVP dramatically delayed the progression of disease, produced higher response rates that lasted longer, and extended survival compared to treatment with CVP alone, according to the July 28, 2008, Journal of Clinical Oncology.
18. Everolimus Extends Progression-Free Survival in Advanced Kidney Cancer
(Posted: 07/30/2008) - A phase III trial testing the drug everolimus in patients with advanced kidney cancer was stopped after an interim analysis showed a significant improvement in progression-free survival, the drug's manufacturer, Novartis, reported February 28, 2008.
19. Osteoporosis Drug Raloxifene Does Not Protect Against Coronary Heart Disease, But Reduces Breast Cancer Risk
(Posted: 08/28/2006, Updated: 07/17/2008) - The drug raloxifene (Evista®) did not prevent heart problems in postmenopausal women with, or at high risk for, coronary heart disease, according to the July 13, 2006, issue of the New England Journal of Medicine.
20. Gemcitabine after Pancreatic Cancer Surgery Improves Survival
(Posted: 06/24/2008) - Patients who received the chemotherapy drug gemcitabine after surgery for pancreatic cancer lived two months longer than patients who had surgery alone, according to findings presented at the 2008 ASCO meeting in Chicago.
< Previous 1 2 3 4 5 6 7 Next >
|
|
|
